These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 16622292)

  • 21. Energy homeostasis and body weight in obesity: new physiopathological and therapeutic considerations.
    Magnati G; Dei Cas A
    Eat Weight Disord; 2000 Sep; 5(3):124-31. PubMed ID: 11082791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological treatment of obesity.
    Mancini MC; Halpern A
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):377-89. PubMed ID: 16767304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuropharmacology of human appetite expression.
    Halford JC; Harrold JA
    Dev Disabil Res Rev; 2008; 14(2):158-64. PubMed ID: 18646016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inverse agonism at α2A adrenoceptors augments the hypophagic effect of sibutramine in rats.
    Janhunen SK; van der Zwaal EM; la Fleur SE; Adan RA
    Obesity (Silver Spring); 2011 Oct; 19(10):1979-86. PubMed ID: 21475142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
    Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Weight reduction. Antiobesity drug treatment in type-2 diabetics].
    Verspohl EJ
    Pharm Unserer Zeit; 2002; 31(3):300-7. PubMed ID: 12071127
    [No Abstract]   [Full Text] [Related]  

  • 28. Monoamine neurocircuitry in depression and strategies for new treatments.
    Hamon M; Blier P
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New and emerging drug molecules against obesity.
    George M; Rajaram M; Shanmugam E
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):65-76. PubMed ID: 24064009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
    Scheen AJ; Ernest P
    Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diet, monoamine neurotransmitters and appetite control.
    Fernstrom JD; Fernstrom MH
    Nestle Nutr Workshop Ser Clin Perform Programme; 2001; 5():117-31; discussion 131-3. PubMed ID: 11510434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A concise review on the therapeutics of obesity.
    Bray GA
    Nutrition; 2000 Oct; 16(10):953-60. PubMed ID: 11054601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sibutramine--a review of clinical efficacy.
    Lean ME
    Int J Obes Relat Metab Disord; 1997 Mar; 21 Suppl 1():S30-6; discussion 37-9. PubMed ID: 9130039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Monoaminergic anorectic agents].
    Fukagawa K; Sakata T
    Nihon Yakurigaku Zasshi; 2001 Nov; 118(5):303-8. PubMed ID: 11729632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine].
    Richter WO
    MMW Fortschr Med; 1999 Dec; 141(49-50):32-6. PubMed ID: 10726144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A benefit-risk assessment of sibutramine in the management of obesity.
    Nisoli E; Carruba MO
    Drug Saf; 2003; 26(14):1027-48. PubMed ID: 14583064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sibutramine: a novel new agent for obesity treatment.
    Ryan DH; Kaiser P; Bray GA
    Obes Res; 1995 Nov; 3 Suppl 4():553S-559S. PubMed ID: 8697058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacologic agents for the treatment of obesity.
    Mathys M
    Clin Geriatr Med; 2005 Nov; 21(4):735-46, vii. PubMed ID: 16182086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].
    Zieba R
    Postepy Hig Med Dosw (Online); 2007 Oct; 61():612-26. PubMed ID: 17971763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis.
    Alexander M; Rothman RB; Baumann MH; Endres CJ; Brasić JR; Wong DF
    Synapse; 2005 May; 56(2):94-9. PubMed ID: 15729739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.